Endovascular treatment in patients with acute ischemic stroke: Technical aspects and results  by Gory, B. et al.
Diagnostic and Interventional Imaging (2014) 95, 561—568
REVIEW / Neuroradiology
Endovascular  treatment  in  patients  with
acute  ischemic  stroke:  Technical  aspects
and  results
B.  Gory,  R.  Riva,  F.  Turjman ∗
Department  of  Interventional  Neuroradiology,  hôpital  neurologique  Pierre-Wertheimer,
hospices civils  de  Lyon,  59,  boulevard  Pinel,  69677  Bron,  France
KEYWORDS
Ischemic  stroke;
Intravenous
thrombolysis;
Mechanical
thrombectomy;
Arterial
recanalization;
Outcome
Abstract  Ischemic  stroke  is  the  primary  cause  of  acquired  disability  in  the  world  and  its
treatment  is  still  a  challenge.  Intravenous  (IV)  thrombolysis  with  recombinant  tissue  plasmino-
gen activator  (rt-PA)  administered  within  4½ hours  of  the  onset  of  the  symptoms  is  the  only
approved  medical  treatment  in  the  acute  phase  of  cerebral  infarction.  However,  its  efﬁcacy  is
limited where  there  is  proximal  intracranial  arterial  occlusion,  and  there  are  many  contraindi-
cations.  The  endovascular  approach,  combined  or  not  with  IV  thrombolysis,  allows  high  rates
of recanalization  to  be  achieved  within  a  short  period  of  time,  with  a  low  rate  of  procedural
complications  when  thrombolysis  is  less  effective  (internal  carotid  artery,  M1  segment  of  the
middle cerebral  artery).  In  these  situations,  endovascular  techniques  are  playing  an  increasing
role in  the  treatment  of  these  patients  even  though  there  is  still  no  indisputable  scientiﬁc  proof
of their  efﬁcacy.  The  priority  at  present  is  to  ﬁnish  the  French  THRACE  study,  but  it  is  already
time to  think  about  the  next  one.
© 2014  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
The  treatment  of  ischemic  stroke,  which  is  the  prime  cause  of  acquired  disability  in  the
world,  is  a  challenge  [1]. There  are  no  methods  for  establishing  the  diagnosis  as  rapidly  as
for  myocardial  infarction,  the  therapeutic  window  is  short  and  no  neuroprotective  agents
have  been  found  to  be  effective  [2].If  there  is  arterial  occlusion,  the  time  that  elapses  is  of  vital  importance,  with  the
death  of  120  million  neurons,  813  billion  synapses  and  714  km  of  neuronal  ﬁbers  each
hour  [3].  In  1995,  the  National  Institute  of  Neurological  Disorders  and  Stroke  (NINDS)
rt-PA  Stroke  Study  marked  a  considerable  advance  by  being  the  ﬁrst  randomized  study
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o  demonstrate  that  a  ﬁbrinolytic  agent  (tissue  plasminogen
ctivator,  alteplase,  Actilyse®)  administered  intravenously
IV)  within  3  hours  of  the  cerebral  ischemia  occurring
esulted  in  clinical  improvement  [4].  It  produced  recovery
n  40%  of  the  patients  by  3  months  (as  against  25%  recovery
ithout  thrombolysis).  At  the  present  time,  IV  rt-PA  within
½ hours  of  the  onset  of  the  symptoms  is  the  only  approved
edical  treatment  in  the  acute  phase  of  an  ischemic  stroke
5].
However,  IV  thrombolysis  is  not  always  effective,  while
iterature  data  indicate  that  endovascular  treatment  can
roduce  high  rates  of  recanalization  within  a  short  time
6],  with  a  low  rate  of  procedural  complications.  Because  of
echnological  advances,  endovascular  techniques  are  play-
ng  an  increasing  role  in  the  treatment  of  ischemic  strokes
ven  though  there  is  still  no  indisputable  scientiﬁc  proof  of
heir  efﬁcacy;  however,  there  is  an  accumulation  of  data
hat  we  can  present.
ntra-arterial ﬁbrinolysis
ntra-arterial  (IA)  thrombolytic  administration  was  evalu-
ted  in  the  PROlyse  in  Acute  Cerebral  Thromboembolism
PROACT  II)  study  in  1998  [7].  PROACT  II  was  a  random-
zed  prospective  study  that  aimed  to  evaluate  the  efﬁcacy
nd  safety  of  IA  pro-urokinase  combined  with  heparin,
ompared  to  heparin  alone,  in  patients  with  occlusion  of
he  middle  cerebral  artery  (MCA)  treated  during  the  ﬁrst
 hours  of  symptoms.  Partial  or  complete  recanalization  was
btained  in  67%  of  the  patients  in  the  endovascular  group  (as
gainst  18%  in  the  control  group).  Of  the  patients  treated
y  the  IA  route,  40%  had  a  favorable  clinical  outcome  at
 months  (modiﬁed  Rankin  Scale,  mRS,  0—2)  (Table  1),
ompared  with  25%  of  the  control  subjects  (P  =  0.04).  Symp-
omatic  intracranial  hemorrhage  occurred  in  10%  of  the
atients  in  the  treated  group  versus  2%  in  the  control  group
P  =  0.006).The  IA  route  has  obvious  theoretical  advantages:  injec-
ion  of  the  thrombolytic  agent  in  contact  with  the  clot,
mmediate  veriﬁcation  of  the  recanalization  and  use  of
Table  1  Modiﬁed  Rankin  Scale  (mRS).
Value  Symptom
0  Asymptomatic
1  Minimal  symptoms,  restriction  of  certain
activities  of  daily  living,  but  patient
autonomous
2  Minor  disability,  restriction  of  certain  activities
of  daily  living,  not  allowing  total  autonomy
3  Moderate  disability,  restriction  of  certain
activities  of  daily  living,  not  allowing  total
autonomy
4  Moderately  severe  disability,  notable
restriction  of  autonomy,  but  not  requiring
continuous  assistance
5  Severe  disability,  bedridden  and  incontinent,
requiring  continuous  nursing
6  Death
m
m
M
T
c
T
s
i
o
r
c
r
I
w
a
r
s
a
b
iB.  Gory  et  al.
 lower  dose  of  rt-PA  with  a  lower  rate  of  hemorrhage.
A  thrombolysis  within  6  hours  of  the  onset  of  symptoms
as  been  recommended  by  the  European  Stroke  Organi-
ation  (ESO)  since  2009  for  occlusions  of  the  MCA  (class
I,  level  B)  and  for  basilar  occlusion  in  selected  patients
class  III,  level  B).  However,  despite  the  recommendations  of
he  American  Heart  Association  (AHA)  and  European  Stroke
rganisation  (ESO)  who  suggest  IA  rt-PA  as  a therapeutic
ption,  only  the  one  clinical  study  has  conﬁrmed  the  efﬁ-
acy  of  this  route  and  the  strategy  has  not  become  widely
ccepted.
rimary stenting
he  use  of  a stent  can  immediately  restore  the  ﬂow  and
void  the  use  of  thrombolytic  drugs.  Instead  of  removing
he  clot,  the  stent  compresses  it  against  the  arterial  wall
hich  prevents  its  becoming  fragmented  distally.  However,
lacement  of  a  stent  may  occlude  perforating  arteries
y  impacting  the  clot  into  their  origins.  In  addition,  the
tent  may  re-occlude  later.  Use  of  a  stent  requires  dual
ntiplatelet  therapy  to  be  initiated,  which  may  increase  the
isk  of  hemorrhagic  transformation.
Primary  stenting  in  acute  ischemic  stroke  has  often  been
art  of  a  multimodal  strategy  for  clots  resisting  other  meth-
ds  of  mechanical  recanalization.  Only  small  series  have
een  reported  in  the  literature.  Brekenfeld  et  al.  [8]  treated
2  patients,  including  7  after  failure  of  another  technique,
ith  a success  rate  of  92%,  and  Linfante  et  al.  [9]  reported
alvage  procedures  in  19  patients  with  a 95%  rate  of  recanal-
zation.
In  the  only  prospective  study,  Stent-Assisted  Recanal-
zation  for  Acute  Ischemic  Stroke  (SARIS),  Levy  et  al.  [10]
eported  complete  recanalization  in  20  patients  within
 hours  of  the  stroke,  but  several  other  endovascular  tech-
iques  were  used  (63.2%).  A  favorable  clinical  outcome  at  6
onths  (mRS  0—2)  was  reported  in  55%  of  the  cases  and  a
ortality  rate  of  35%.
echanical thrombectomy
he  last  10  years  have  seen  major  developments  in  endovas-
ular  devices  for  removing  clots  in  acute  ischemic  stroke.
wo  devices,  the  MERCI  retriever  (2004)  and  the  Penumbra
ystem  (2007),  have  been  approved  by  the  FDA  for  withdraw-
ng  a  thrombus  in  the  ﬁrst  8  hours  after  a  stroke.
Thrombectomy  allows  more  rapid  recanalization  of  the
ccluded  vessels.  The  FDA’s  decision  was  based  on  non-
andomized  studies  comparing  the  procedure  with  historical
ontrol  of  the  PROACT  II  data.  In  these  studies,  the  rates  of
ecanalization  were  higher  than  those  reported  in  studies  of
V  rt-PA,  the  rates  of  symptomatic  intracerebral  hemorrhage
ere  comparable  but  the  rates  of  good  functional  outcome
t  3  months  were  poorer  than  those  of  the  IV  studies.  These
esults  were  in  part  explained  by  greater  initial  clinical
everity  and  the  later  time  of  treatment.  These  devices  are
ccepted  as  useful  for  withdrawing  the  clot  in  acute  stroke
ut  have  not  been  approved  by  the  FDA  as  being  effective
n  clinical  use.
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gEndovascular  treatment  in  patients  with  acute  ischemic  stro
The MERCI retriever
This  is  a  nitinol  wire  forming  5  turns  of  a  helix  decreasing
in  size  towards  its  end,  giving  it  a  cork-screw  appearance.
This  device  is  led  through  the  microcatheter  into  the  clot
where  it  opens  like  a  cork-screw,  then  the  whole  unit  is  with-
drawn  from  the  circulation  removing  the  occlusive  clot  in  the
artery.
This  device  was  used  in  the  Mechanical  Embolus  Removal
in  Cerebral  Ischemia  (MERCI)  study  [11]  which  assessed  the
safety  and  efﬁcacy  of  the  MERCI  retriever,  during  the  8  hours
following  a  stroke,  in  151  patients  who  were  not  eligible
for  thrombolysis  (median  NIHSS  of  20).  The  National  Insti-
tute  of  Health  Stroke  Scale  (NIHSS)  is  a  scale  of  15  items
allowing  quantiﬁcation  of  neurological  deﬁciencies  observed
during  the  examination.  It  evaluates  vigilance,  eye  move-
ments,  visual  ﬁeld,  facial  motricity,  segmental  strength  of
the  extremities,  sensitivity,  coordination,  language,  articu-
lation  and  inattention.  Arterial  recanalization  was  obtained
in  46%  of  the  patients  treated,  much  higher  than  in  the
control  group  (spontaneous  recanalization  of  18%  in  the
PROACT  II  study).  Favorable  clinical  outcome  was  obtained
in  27.7%  of  the  patients.  The  mean  duration  of  the  proce-
dure  was  2.1  hours.  Procedural  complications  with  clinical
consequences  occurred  in  5.5%  of  the  patients  and  the  rate
of  intracranial  hemorrhage  was  7.8%.
The  Multi-MERCI  study  [12]  was  an  international  study
with  only  one  arm  which  evaluated  164  patients  (median
NIHSS  of  19)  in  the  8  hours  following  occurrence  of  the  symp-
toms.  The  principal  objective  was  arterial  recanalization.
Preliminary  treatment  with  rt-PA  (IV  or  IA),  or  the  use  of
another  mechanical  device  was  allowed.  Recanalization  was
achieved  in  57.3%  of  cases  with  the  MERCI  retriever  alone
and  in  69.5%  of  cases  when  associated  with  other  proce-
dures.  A  favorable  clinical  outcome  (mRS  0—2)  was  obtained
in  36%  of  the  cases  at  3  months,  while  34%  died.  The  mean
duration  of  the  procedure  was  1.6  hours.
The  introduction  of  the  MERCI  retriever  was  a  decisive
advance  in  the  endovascular  approach  to  strokes.  The  two
MERCI  studies  showed  signiﬁcant  improvement  in  the  clinical
outcome  in  recanalized  patients.
The Penumbra system
The  Penumbra  system  is  a  continuous  clot  aspiration  sys-
tem  combined  with  mechanical  fragmentation  of  the  clot.
Catheters  of  different  diameters  are  brought  into  contact
with  the  proximal  part  of  the  clot  and  connected  to  a  suction
pump  (−700  mmHg).  To  avoid  obstruction  of  the  catheter,
the  clot  is  also  fragmented  using  a  separator  at  the  end  of  a
microguide.
The  Penumbra  Stroke  Trial  [13]  reported  125  patients
(median  NIHSS  of  18)  treated  within  a  mean  time  of
4.3  hours.  Recanalization  was  obtained  in  81.6%  of  the  cases.
Favorable  clinical  outcome  (mRS  0—2)  was  obtained  in  25%
of  all  the  patients  and  29%  of  the  recanalized  patients.  The
rate  of  symptomatic  intracranial  hemorrhage  was  11.2%  and
overall  mortality  was  32.8%.  The  late  treatment  of  these
patients  might  explain  this  disappointing  rate  of  favorable
clinical  outcome.
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tent retrievers (SR)
urrently,  these  are  the  most  used  devices.  They  provide  a
igh  rate  of  arterial  recanalization  in  a  short  time.  These
echanical  thrombectomy  devices  are  self-expanding,
esigned  as  stents  ﬁxed  to  their  deployment  system  and
hus  not  spontaneously  detachable  (Fig.  1).  They  combine
he  advantages  of  inserting  a  temporary  stent  with  immedi-
te  restoration  of  the  ﬂow  and  the  possibility  of  removing
he  clot.
These  devices  are  used  as  stents.  The  clot  is  crossed
ith  a  microcatheter,  then  the  SR  is  deployed  to  include
he  whole  of  the  thrombus.  The  radial  force  of  the  stent
pens  it  up  to  restore  the  blood  ﬂow,  pushing  the  throm-
us  against  the  wall  of  the  artery.  The  SR  is  then  removed
fter  several  minutes,  during  which  time  the  clot  will  have
ecome  anchored  in  the  stent’s  mesh.  Temporary  proximal
cclusion  of  the  cervical  artery  by  a  balloon  catheter  and
uction  can  be  combined  with  this  technique  and  seem  to
mprove  the  results  by  limiting  the  risk  of  distal  emboli
hen  the  thrombus  is  removed.  There  are  many  models
f  SR,  and  the  ﬁrst  used  was  the  Solitaire  in  March  2008
14].
Several  series  have  been  reported  since  then:
Castano  et  al.  [15]  reported  a  series  of  20  patients
reated  within  8  hours  of  anterior  circulation  infarction.
omplete  recanalization  was  obtained  in  90%  of  the  cases
ith  the  mean  duration  of  the  procedure  being  50  minutes.
 clinically  favorable  outcome  (mRS  0—2)  was  obtained
n  45%  of  the  patients  at  3  months.  The  rate  of  symp-
omatic  hemorrhagic  complications  was  10%  and  mortality
8.1%.
The  SWIFT  study  [16]  was  a  randomized  study  comparing
he  efﬁcacy  and  safety  of  the  Solitaire  device  with  the  MERCI
etriever.  The  patients  were  within  8  hours  of  the  onset  of
ymptoms  and  were  ineligible  for  IV  thrombolysis  or  it  had
ailed  for  them.  The  principal  objective  was  recanalization
f  an  occluded  target  artery  with  a  TIMI  ﬂow  ≥  2  (Table  2).
he  Solitaire  device  produced  better  angiography  results
61%  versus  24%),  increased  safety  (mortality  at  3  months:
7%  versus  38%),  and  an  improvement  in  clinical  outcome  at
 months  (58%  versus  33%,  OR:  2.78,  P  =  0.0001)  compared
ith  the  MERCI  retriever.
There  are  moreover  many  other  series  which  have  given
imilar  results.  The  methodology  is  not  perfect  as  the  control
roups  are  historical.  However,  the  results  are  impressive:
Vendrell  et  al.  [17]  reported  a  series  of  24  patients
reated  within  less  than  4½ hours  of  the  onset  of  stroke
ue  to  isolated  occlusion  of  the  MCA.  All  the  patients  had
V  thrombolysis  and  if  the  IV  route  failed  (deﬁned  as  the
bsence  of  improvement  1  hour  after  beginning  the  infu-
ion),  mechanical  thrombectomy  with  the  Solitaire  device
as  performed.  The  patients  were  selected  on  the  basis  of
iffusion-weighted  MRI  with  an  ASPECT  score  <  5  (Fig.  2).
his  group  was  compared  with  a  historical  series  of  32
atients  treated  by  IV  thrombolysis  only  and  selected  on  the
ame  criteria.  There  was  no  cerebral  hemorrhage  in  the  2
roups.  At  3  months,  77%  of  the  patients  in  the  endovascu-
ar/IV  group  had  an  mRS  score  ≤  2  as  against  50%  in  the  IV
roup  (P  <  0.02).
Leker  et  al.  [18]  reported  a  prospective  series  of  22
atients  (median  NIHSS  of  21)  with  occlusion  of  the  MCA
564  B.  Gory  et  al.
Figure 1. 65-year-old male patient, with a history of a right temporal infarct 1 month previously (star), presenting left hemiplegia: a:
cerebral CT, axial slice, without enhancement showing the right anterior temporal ischemic sequela without signs of recent hemorrhage; b:
perfusion CT, axial slice. Note the large area of hypoperfusion in the territory of the right middle cerebral artery; c: cerebral angiogram,
antero-posterior projection, after injection of the right common carotid artery. Note (arrow) the complete occlusion of the proximal M1
segment of the middle cerebral artery; d: solitaire stent retriever showing the clot in the mesh of the stent; e: cerebral angiogram, antero-
posterior projection, after injection of the right common carotid artery showing complete recanalization of the artery (TICI 3) 42 minutes
a  with diffusion-weighted imaging sequence. Excluding a few very small
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Table  2  TICI  Score  (Thrombolysis  In  Cerebral
Infarction).
Value  Angiographic  appearance
0  No  perfusion
1 Minimal  perfusion
2a  Partial  perfusion  <  50%  of  the  territory  of  the
occluded  artery
2b  Partial  perfusion  ≥  50%  of  the  territory  of  the
occluded  artery
3  Complete  perfusion  of  all  the  arterial  branches
p
d
cfter femoral arterial puncture; f: cerebral MR imaging, axial slice,
schemic lesions, the whole of the MCA territory has been reperfuse
reated  by  mechanical  thrombectomy  and  a  group  of  66
atients  (median  NIHSS  of  14.5)  treated  by  IV  thromboly-
is.  The  length  of  time  to  treatment  was  240  minutes  in  the
ndovascular  group  as  against  95  minutes  in  the  IV  group.  At
 months,  an  mRS  score  ≤  2  was  obtained  in  60%  of  the  cases
n  the  thrombectomy  group  as  against  37.5%  in  the  IV  group
P  =  0.001).
The  results  of  an  international,  prospective  series  of
atients  with  acute  ischemic  stroke  treated  by  thrombec-
omy  with  the  Solitaire  device  have  been  published  recently
19].  Among  the  patients  with  proximal  occlusion  of  an
rtery  of  the  anterior  circulation,  202  were  treated  within
 hours  of  the  onset  of  symptoms  in  14  expert  centers  in
urope,  Canada  and  Australia.  Strict  criteria  were  applied
o  the  selection  of  the  centers.  The  primary  objective  was
he  level  of  revascularization  determined  by  an  indepen-
ent  observer.  The  secondary  objective  was  the  functional
utcome  at  3  months  deﬁned  as  an  mRS  score  between  0
nd  2.  The  median  initial  NIHSS  was  17,  the  mean  age  was
2  years.  Eighty-two  percent  of  the  patients  had  occlusion
f  the  MCA  and  18%  of  the  internal  carotid  artery.  Satisfac-
ory  recanalization  (TICI  2b  or  3)  was  achieved  in  79.2%  of
t
6
m
iatients.  Adverse  procedural  events  or  events  related  to  the
evice  were  observed  in  7.4%  of  the  cases  and  symptomatic
erebral  hemorrhage  in  1.5%.  There  was  a  favorable  func-
ional  outcome  in  57.9%  of  cases  and  the  mortality  rate  was
.9%.  These  results  seem  to  suggest  that  how  stroke  treat-
ent  managed  in  a given  center  could  be  a  decisive  factor
n  endovascular  treatment.
Endovascular  treatment  in  patients  with  acute  ischemic  stroke  565
Figure 2. ASPECT score. Two non-enhanced cerebral CT axial slices are used: a: slice through the basal ganglia; b: slice 2 cm above the
r eac
2, M3
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Tprevious one through the semi-oval centers. A point is deducted fo
nucleus; L, lentiform nucleus; IC, internal capsule; I, insula; M1, M
posterior cortex. A normal cerebral CT has a score of 10.
Combined treatment
IV + IA bridging
In  the  bridging  strategy,  the  procedure  begins  with  the  IV
injection  of  a  thrombolytic  agent,  the  IA  procedure  being
used  if  the  ﬁrst  approach  fails.
The  Emergency  Management  of  Stroke  (EMS)  bridging  trial
[20]  compared  the  efﬁcacy  of  the  combined  IV  and  IA  strat-
egy  with  the  IA  technique  alone,  started  within  the  ﬁrst
3  hours  after  the  onset  of  symptoms.  The  recanalization  rate
was  higher  with  the  combined  strategy  but  it  did  not  result
in  a  clinical  improvement.
In  the  Interventional  Management  of  Stroke  (IMS  I)  study
[21],  80  patients  with  intracranial  arterial  occlusion  con-
ﬁrmed  by  angiography  were  treated  within  the  ﬁrst  3  hours
with  an  IV  dose  of  0.6  mg/kg  of  rt-PA.  If  necessary,  IA  treat-
ment  was  used  in  addition  to  the  IV  dose.  The  results  were
compared  with  the  results  of  placebo  or  IV  treatment  in  the
NINDS  study.  The  rates  of  intracerebral  hemorrhage  were
identical  in  the  3  groups  but  the  patients  of  the  IMS  study
had  a  signiﬁcantly  better  outcome  at  3  months.
The  IMS  II  study  [22]  showed  that  combined  IV  and  IA  ﬁb-
rinolysis  resulted  in  an  additional  beneﬁt.  Ultrasound  was
also  added  to  improve  clot  lysis.  Patients  who  received  the
combined  treatment  had  a  better  clinical  outcome  at  3
months  (mRS  0—2)  than  those  in  the  placebo  group  and  the
rt-PA  group  of  the  NINDS  study  (46%,  39%  and  28%,  respec-
tively).
Since  then,  more  or  less  sophisticated  ultrasound  (EKOS)
[23]  or  laser  (EPAR)  techniques  of  clot  fragmentation  have
been  used  but  have  not  become  widely  popular.  Devices
for  thrombectomy  (the  MERCI  retriever)  and  thrombo-
aspiration  (the  Penumbra  system)  were  approved  in  2004  and
2007  by  the  Food  and  Drug  Administration  (FDA),  followed
in  2008  by  the  arrival  of  a  new  concept,  stent  retriev-
ers.
I
b
o
Th of the following 10 regions when they are affected: C, caudate
, anterior, lateral, posterior cortex; M4, M5, M6, anterior, lateral,
V + endovascular (IA or mechanical)
his  strategy  seems  to  combine  the  best  of  both  approaches,
he  rapidity  and  simplicity  of  the  IV  approach  and  the  greater
fﬁcacy  of  the  endovascular  method.
The  French  REvascularization  using  Combined  intra-
enous  Alteplase  and  Neurointerventional  ALgorythm  for
cute  Ischemic  StrokE  (RECANALISE)  study  [24]  compared
n  IV  strategy  and  a  combined  IV/endovascular  strategy
n  patients  with  intracranial  arterial  occlusion  conﬁrmed
y  CT  or  MR  angiography.  The  endovascular  approach
onsisted  of  IA  injection  of  a  thrombolytic  agent  (IA  rt-
A,  0.3  mg/kg)  with  in  addition,  if  necessary,  mechanical
hrombectomy.  This  combined  strategy  has  shown  that  an
V/endovascular  approach  had  a  higher  rate  of  recanal-
zation  (87%  versus  52%,  P  =  0.0002)  but  did  not  lead  to
 signiﬁcant  clinical  improvement  at  3  months  (57%  ver-
us  44%,  P  =  0.13).  This  approach  was  not  associated  with
igher  morbidity/mortality  (17%  in  both  groups  for  mor-
ality;  11%  versus  9%  for  symptomatic  hemorrhage,  for  IV
hrombolysis  and  the  combined  approach,  respectively).
his  study  emphasized  that  each  half  hour  lost  before
btaining  recanalization  is  associated  with  20%  fewer  favor-
ble  outcomes.
MS 3, MR RESCUE, and SYNTHESIS
xpansion studies: is there still a place for
he  endovascular approach in acute
schemic stroke patients?
he  IMS  III  study  [25]  was  a  multicenter,  randomized,  phase
II  study  comparing  an  IV  strategy  with  an  approach  com-
ining  an  IV  and  an  endovascular  route  using  either  IA  rt-PA
r  a  mechanical  endovascular  device  approved  by  the  FDA.
he  objective  was  to  show  the  superiority  of  the  combined
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pproach  over  IV  rt-PA  alone.  The  2  strategies  had  to  be
tarted  within  3  hours  of  the  cerebral  stroke  occurring.  After
ncluding  656  patients  out  of  900  in  50  international  sites,
he  study  was  suspended  in  April  2012  due  to  the  absence
f  additional  beneﬁt  from  the  endovascular  strategy.  Three
evices  were  approved,  the  MERCI  (2004),  the  Penumbra
2007)  and  the  Solitaire  (March  2012).  The  clinical  results
f  IMS  III  cannot  be  generalized  to  SR  since  only  a  small
umber  of  procedures  with  these  devices  were  included.
mong  the  patients  included  in  the  endovascular  group,
0.8%  had  a  favorable  clinical  outcome  (mRS  0—2)  compared
ith  38.7%  of  the  patients  treated  with  IV  rt-PA  alone.  There
as  no  increase  in  mortality  at  90  days  in  the  endovascu-
ar  group  (19.1%  versus  21.6%;  P  =  0.52),  nor  in  symptomatic
erebral  hemorrhage  within  30  days  (6.2%  versus  5.9%;
 <  0.83).
The  Mechanical  Retrieval  and  REcanalization  of  Stroke
lots  Using  Embolectomy  (MR  RESCUE)  trial  [26]  was  a
ulticenter,  randomized,  phase  2b  study  comparing  an  IV
ith  an  endovascular  strategy  (MERCI  or  Penumbra  devices).
ollowing  infarction  of  their  anterior  circulation  less  than
 hours  previously,  118  patients  were  randomized  in  22
orth-American  centers  between  2004  and  2011.  The  ran-
omization  was  stratiﬁed  depending  on  the  presence  or  not
f  a  penumbra.  Among  the  patients,  58%  had  a penum-
ra  on  inclusion.  Revascularization  (TICI  2a,  2b  or  3)  was
chieved  in  67%  of  the  patients.  There  was  no  difference  in
he  mean  mRS  score  between  the  two  groups  (3.9  versus  3.9;
 =  0.99).  The  endovascular  approach  was  not  superior  to  IV
t-PA  either  for  the  patients  with  a  penumbra  (mean  mRS
.9  versus  3.4;  P  =  0.23)  or  without  a  penumbra  (4.0  versus
.4;  P  <  0.32).
The  Local  versus  Systemic  Thrombolysis  for  Acute
schemic  Stroke  (SYNTHESIS)  [27]  trial  was  a  multicenter,
andomized  study  comparing  an  IV  with  an  endovascular
trategy.  A  total  of  181  patients  were  included  in  each  group.
he  mean  length  of  time  between  the  onset  of  symptoms  and
he  beginning  of  IV  rt-PA  was  2.75  hours  and  between  the
nset  of  the  symptoms  and  the  beginning  of  the  endovas-
ular  treatment  was  3.75  hours  (P  <  0.001).  At  3  months,  55
atients  (30.4%)  had  a  favorable  clinical  outcome  (mRS  0—1)
ompared  with  63  patients  (34.8%)  in  the  IV  rt-PA  group
P  =  0.16).  The  rate  of  cerebral  hemorrhage  within  7  days
as  6%  in  both  the  groups.
However,  these  studies  had  several  weak  points:  a  low
ate  of  inclusion  (2  patients  per  center  per  year  in  IMS
II,  3.5  patients  per  center  per  year  in  SYNTHESIS),  long
eriods  to  revascularization  (mean  time  to  arterial  puncture
as  3  hours  28  minutes,  mean  time  to  reperfusion  5  hours
5  minutes  in  IMS  III),  a  poorly  selected  population  (only  46%
f  the  patients  included  had  had  a  CT  angiogram,  18.9%  of
hose  in  the  endovascular  group  did  not  have  intracranial
rterial  occlusion  in  IMS  III),  the  use  of  obsolete  measures  (IA
t-PA  in  37.8%  of  patients,  mechanical  thrombectomy  with
rst  generation  devices  in  34.3%  of  cases,  and  second  gener-
tion  in  1.2%  of  cases  in  IMS  III,  IA  rt-PA  in  66.1%  of  patients
n  SYNTHESIS).
THRACE  is  a  French  multicenter  randomized  study  to
etermine  whether  a  combined  IV  thrombolysis  and  mechan-
cal  thrombectomy  approach  is  superior  to  the  standard
reatment  with  IV  thrombolysis  in  the  4  hours  following
he  onset  of  the  symptoms  in  patients  with  occlusion  of
C
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tB.  Gory  et  al.
he  proximal  cerebral  arteries  with  moderate  to  severe
eurological  impact  (NIHSS  ≥  10).  The  ongoing  study  should
nclude  480  patients,  240  in  each  arm.  The  hypothesis  is
 15%  improvement  in  the  functional  outcome  (mRS  0—2)
or  combined  approach  patients.  An  interim  analysis  on  220
atients  has  been  carried  out.  The  principal  objective  of
5%  functional  beneﬁt  has  not  been  reached.  However,  the
hrombectomy  has  not  been  associated  with  an  increase  in
orbidity/mortality.
rospects for the treatment of acute
erebral infarction
election by imaging
everal  retrospective  observational  studies  support  the  use
f  multimodal  MR  imaging  for  selecting  patients  more  than
½ hours  after  the  occurrence  of  symptoms.  MR  imaging
eems  to  provide  a  sure  way  of  selecting  patients;  if  the  vol-
me  affected  in  diffusion  is  small  and  the  perfusion  deﬁcit
s  large,  there  is  a diffusion/perfusion  mismatch  and  it may
e  useful  to  initiate  thrombolysis.
Among  the  patients,  72  were  treated  between  3  and
 hours  of  the  onset  of  a  stroke  by  applying  this  strat-
gy  in  the  Diffusion-weighted  imaging  for  Understanding
troke  Evolution  (DEFUSE)  study  [28].  The  patients  with
 diffusion/perfusion  mismatch  had  the  treatment.  Half
f  the  patients  included  did  not  have  a mismatch  and
ere  not  treated.  It  was  also  shown  that  permeabil-
ty  modiﬁcations  detected  with  MR  imaging  might  predict
he  occurrence  of  hemorrhagic  complications  after  rt-
A.
Another  study,  the  Echo  Planar  Imaging  Thrombolysis
valuation  Trial  (EPITHET)  [29,30]  used  perfusion/diffusion
o  include  patients  for  treatment  with  rt-PA  between  3  and
 hours  of  occurrence  of  their  stroke.  IV  rt-PA  reduced  the
ize  of  regions  irreversibly  destroyed  and  improved  the  clin-
cal  prognosis  of  patients  with  an  MR  imaging  mismatch
efore  treatment.
The  DEFUSE  2  study  [31]  included  patients  with  a
troke  within  the  previous  12  hours,  for  whom  endovascular
ecanalization  was  planned  when  an  MR  imaging  diffu-
ion/perfusion  mismatch  had  been  found  by  the  RAPID
rogram.  Patients  with  a  mismatch  were  more  likely  to
ave  a  favorable  outcome  after  recanalization.  The  asso-
iation  between  reperfusion  and  favorable  outcome  did  not
ecrease  with  the  length  of  time  in  patients  with  a  per-
usion/diffusion  mismatch,  lending  weight  to  the  idea  that
iable  tissue  could  be  saved  during  several  hours,  without
oubt  due  to  pial  anastomoses.
At present,  the  only  validated  biomarker  is  based  on
xtent  of  the  cerebral  infarction  established  from  the
SPECT  score  [32—34].
echnical aspectsertain  technical  aspects  are  not  ﬁxed:  the  use  of  proxi-
al  vascular  protection,  the  use  of  thrombolytics  via  the  IA
oute,  the  use  of  general  anesthesia  or  sedation.  The  optimal
ime  to  thrombectomy  is  not  known,  but  it  is  limited.
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Conclusion
IV  thrombolysis  with  rt-PA  is  effective  in  the  acute  phase
of  cerebral  infarction  and  must  be  implemented  without
losing  time.  However,  its  efﬁcacy  is  limited  and  there  are
many  contraindications.  Endovascular  mechanical  recanal-
ization  devices  produce  recanalization  which  is  generally
effective  and  rapid  in  cases  of  proximal  intracranial  arte-
rial  occlusion,  where  IV  thrombolysis  is  less  effective.  They
can  be  used  in  addition  to  or  as  an  alternative  to  IV  throm-
bolysis.  At  present,  however,  endovascular  revascularization
has  not  yet  resulted  in  clinical  improvement  in  a  random-
ized  study.  At  the  least,  mechanical  thrombectomy  does  not
increase  the  rate  of  symptomatic  cerebral  hemorrhage  and
gives  results  equivalent  to  IV  thrombolysis.  It  can  therefore
be  offered  where  there  are  contraindications  to  IV  throm-
bolysis  [30].
Mechanical  endovascular  thrombectomy  necessitates  rig-
orous  hospital  organization  in  which  all  those  involved
(neurologists,  diagnostic  neuroradiologists,  anesthetists  and
experienced  interventional  neuroradiologists)  are  available
and  can  go  into  action  extremely  rapidly.  The  priority  at
present  is  to  ﬁnish  the  French  THRACE  study,  but  it  is  already
time  to  think  about  the  next  trial.
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